Fruquintinib
| CAS No. | 1194506-26-7 |
|---|---|
| MDL No. | N/A |
| MF | C21H19N3O5 |
| MW | 393.40 |
| InChI Key | BALLNEJQLSTPIO-UHFFFAOYSA-N |
Pricing & Availability
| Pack Size | Purity | Price | Availability | Action |
|---|---|---|---|---|
| - | - | On Request | On Request | |
| Custom synthesis and bulk supply options are available upon request. | ||||
Product Information
Fruquintinib is a quinazoline derivative substituted with [2-methyl-3-(methylcarbamoyl)-1-benzofuran-6-yl]oxy at position 4, methoxy at position 6, and methoxy at position 7. It is a highly potent and selective inhibitor of VEGFR1, VEGFR2, and VEGFR3 (IC50 = 33, 0.35, and 35 nM), used in the treatment of metastatic colorectal cancer. It functions as an EC 2.7.10.1 (receptor protein-tyrosine kinase) inhibitor, an antineoplastic agent, and a vascular endothelial growth factor receptor antagonist. It belongs to the classes of quinazolines, aromatic ethers, 1-benzofurans, and secondary carboxamides.
| CAS No. | 1194506-26-7 |
|---|---|
| Product Name | Fruquintinib |
Biological Targets
FLT1·FLT4·KDR
Associated Conditions
pancreatic carcinoma·stomach neoplasm·soft tissue sarcoma·cancer·rectum cancer·
* The information provided here is compiled from public sources and is for reference only.
